Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cecil Czerkinsky

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2022
A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 SubjectsEmanuela Martinuzzi, Jonathan Benzaquen, Olivier Guerin, et al.
Vaccine|July 6, 2010
A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteersHee-Chang Jang, Choong Jong Kim, Kye Hyoung Kim, et al.
Journal of Clinical Microbiology|March 20, 2009
Cholera outbreaks caused by an altered Vibrio cholerae O1 El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007 to 2008Binh Minh Nguyen, Je Hee Lee, Ngo Tuan Cuong, et al.
Clinical and Vaccine Immunology : CVI|February 6, 2015
Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infectionJae-Ouk Kim, Semi Rho, Su Hee Kim, et al.
Immunology Letters|March 9, 2005
Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNAJan Holmgren, Jenni Adamsson, Fabienne Anjuère, et al.
Plos One|April 21, 2010
Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in miceHuan H Nguyen, Terrence M Tumpey, Hae-Jung Park, et al.
Ebiomedicine|November 11, 2021
Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipientsFilippo Massa, Marion Cremoni, Alexandre Gérard, et al.
Heliyon|February 15, 2017
Comparison of IPV to tOPV week 39 boost of primary OPV vaccination in Indian infants: an open labelled randomized controlled trialSuman Kanungo, Deok Ryun Kim, Bisakha Haldar, et al.
Heliyon|March 22, 2018
Antibody secreting B cells and plasma antibody response to rotavirus vaccination in infants from Kolkata IndiaAnuradha Sinha, Suman Kanungo, Deok Ryun Kim, et al.
Journal of Medical Microbiology|December 17, 2009
Classical RS1 and environmental RS1 elements in Vibrio cholerae O1 El Tor strains harbouring a tandem repeat of CTX prophage: revisiting Mozambique in 2005Seon Young Choi, Je Hee Lee, Eun Jin Kim, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2022
A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 SubjectsEmanuela Martinuzzi, Jonathan Benzaquen, Olivier Guerin, et al.
Vaccine|July 6, 2010
A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteersHee-Chang Jang, Choong Jong Kim, Kye Hyoung Kim, et al.
Journal of Clinical Microbiology|March 20, 2009
Cholera outbreaks caused by an altered Vibrio cholerae O1 El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007 to 2008Binh Minh Nguyen, Je Hee Lee, Ngo Tuan Cuong, et al.
Clinical and Vaccine Immunology : CVI|February 6, 2015
Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infectionJae-Ouk Kim, Semi Rho, Su Hee Kim, et al.
Immunology Letters|March 9, 2005
Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNAJan Holmgren, Jenni Adamsson, Fabienne Anjuère, et al.
Plos One|April 21, 2010
Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in miceHuan H Nguyen, Terrence M Tumpey, Hae-Jung Park, et al.
Ebiomedicine|November 11, 2021
Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipientsFilippo Massa, Marion Cremoni, Alexandre Gérard, et al.
Heliyon|February 15, 2017
Comparison of IPV to tOPV week 39 boost of primary OPV vaccination in Indian infants: an open labelled randomized controlled trialSuman Kanungo, Deok Ryun Kim, Bisakha Haldar, et al.
Heliyon|March 22, 2018
Antibody secreting B cells and plasma antibody response to rotavirus vaccination in infants from Kolkata IndiaAnuradha Sinha, Suman Kanungo, Deok Ryun Kim, et al.
Journal of Medical Microbiology|December 17, 2009
Classical RS1 and environmental RS1 elements in Vibrio cholerae O1 El Tor strains harbouring a tandem repeat of CTX prophage: revisiting Mozambique in 2005Seon Young Choi, Je Hee Lee, Eun Jin Kim, et al.
Pageof 6